ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL


This announcement contains inside information

09 August 2016 07:00

ASTRAZENECA PROVIDES UPDATE ON PHASE III TRIAL OF SELUMETINIB IN NON-SMALL CELL
LUNG CANCER

Selumetinib did not meet trial endpoint of progression-free survival in KRASm
NSCLC patients

AstraZeneca today announced results from the Phase III SELECT-1 trial of the MEK
1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd
-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced
or metastatic non-small cell lung cancer (NSCLC).

The results showed that the trial did not meet its primary endpoint of
progression-free survival (PFS), and selumetinib did not have a significant
effect on overall survival (OS). The adverse event profiles for selumetinib and
docetaxel were consistent with those seen previously.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief
Medical Officer at AstraZeneca, said: "A randomised Phase II trial showed
promising activity of selumetinib in combination with docetaxel in patients with
KRAS mutation-positive lung cancer. It is disappointing for patients that these
results have not been confirmed in Phase III. We expect to present data at a
forthcoming medical meeting. We remain committed to further developing
treatments in the lung cancer setting, such as our immunotherapy combinations
and targeted EGFR treatments."

SELECT-1 is an international trial with 510 randomised patients in over 200
centres. Patients received either selumetinib (75mg, orally, twice daily) or
placebo in combination with docetaxel (intravenously, 75mg/m2, on day one of
every 21-day cycle).

Selumetinib is being explored as a treatment option in registration-enabling
studies in patients with differentiated thyroid cancer where the treatment
received Orphan Drug Designation (https://www.astrazeneca.com/media-centre/press
-releases/2016/selumetinib-granted-orphan-drug-designation-in-the-US-for
-adjuvant-treatment-of-differentiated-thyroid-cancer-12052016.html), and
patients with neurofibromatosis type 1, a genetic disorder that causes tumours
to grow along nerve tissue.1

About KRASm non-small cell lung cancer
KRAS is one of the most common genetic mutations in NSCLC, and is found in 30%
of patients.2 Adenocarcinomas make up the majority of cases with KRAS mutations,
which are less common in squamous cell NSCLC.2,3

KRAS mutations are associated with activation of the RAS-ERK signalling pathway,
which drives tumour growth.3

About selumetinib (AZD6244, ARRY-142886)
Selumetinib is an oral, potent and highly selective MEK 1/2 inhibitor. MEK 1/2
are critical components of the RAS-ERK pathway, activation of which is
implicated in driving cancer growth and progression, including in patients with
KRASm NSCLC.4,5

AstraZeneca acquired exclusive worldwide rights to selumetinib from Array
BioPharma Inc. (NASDAQ: ARRY) in 2003.

In May 2016 (https://www.astrazeneca.com/media-centre/press
-releases/2016/selumetinib-granted-orphan-drug-designation-in-the-US-for
-adjuvant-treatment-of-differentiated-thyroid-cancer-12052016.html), selumetinib
was granted Orphan Drug Designation by the US Food and Drug Administration (FDA)
for adjuvant treatment of patients with stage III or IV differentiated thyroid
cancer (DTC), and AstraZeneca is committed to exploring its full potential,
including in Phase III trials in patients with DTC and in a US National Cancer
Institute-sponsored Phase II registration trial in patients with paediatric
neurofibromatosis type 1.

About SELECT-1
SELECT-1 (NCT01933932 (https://clinicaltrials.gov/ct2/show/NCT01933932)) is a
Phase III, double-blind, randomised, placebo-controlled trial. It is designed to
assess the efficacy and safety of selumetinib (75 mg twice daily, given orally
on a continuous schedule) in combination with docetaxel (75 mg/m2 intravenously
on day 1 of every 21-day cycle), compared with matched placebo in combination
with docetaxel (same schedule) in 510 patients receiving 2nd-line treatment for
KRASm locally advanced or metastatic NSCLC (stage IIIB-IV), confirmed by central
testing of tumour tissue using the cobas® KRAS Mutation Test (Roche Molecular
Systems).3

The primary endpoint is PFS, and secondary endpoints include OS, objective
response rate (ORR), duration of response (DoR), and safety and tolerability.3

About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing
portfolio of new medicines that has the potential to transform patients' lives
and the Company's future. With at least 6 new medicines to be launched between
2014 and 2020 and a broad pipeline of small molecules and biologics in
development, we are committed to advance New Oncology as one of AstraZeneca's
six Growth Platforms focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative partnerships
and investments that accelerate the delivery of our strategy, as illustrated by
our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms -- immuno-oncology, the
genetic drivers of cancer and resistance, DNA damage response and antibody drug
conjugates -- and by championing the development of personalised combinations,
AstraZeneca has the vision to redefine cancer treatment and one day eliminate
cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three main therapy areas -
Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and
Oncology. The Company is also active in inflammation, infection and neuroscience
through numerous collaborations. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide. For more
information please visit: www.astrazeneca.com.

References

1 U.S. National Library of Medicine. Genetics Home Reference: neurofibromatosis
type 1. Published 5 July 2016. Available at
https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1. Accessed 6 July
2016.

2  Dearden S  (http://www.ncbi.nlm.nih.gov/pubmed/23723294)et
al (http://www.ncbi.nlm.nih.gov/pubmed/23723294). Mutation incidence and
coincidence in non small
-cell (http://www.ncbi.nlm.nih.gov/pubmed/23723294)  (http://www.ncbi.nlm.nih.go
v 
/pubmed/23723294)lung cancer (http://www.ncbi.nlm.nih.gov/pubmed/23723294): meta
-analyses by ethnicity and histology
(mutMap). (http://www.ncbi.nlm.nih.gov/pubmed/23723294) Ann Oncol. 2013
Sep;24(9):2371-6.

3  Jänne
PA (http://www.ncbi.nlm.nih.gov/pubmed/?term=J%C3%A4nne%20PA%5BAuthor%5D&cauthor
= 
true&cauthor_uid=26837474) et al. Study design and rationale for a randomized,
placebo-controlled, double-blind study to assess the efficacy and safety
of selumetinib in combination with docetaxel as second-line treatment in
patients with KRAS-mutant advanced non-small cell lung cancer (SELECT-1). Clin
Lung Cancer  (http://www.ncbi.nlm.nih.gov/pubmed/26837474)2016 Mar;17(2):e1-4

4 Davies BR, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen
-activated protein kinase/extracellular signal-regulated kinase kinase 1/2
kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic
relationship, and potential for combination in preclinical models. Mol Cancer
Ther 2007;6:2209-19.

5 Roberts PJ, Stinchcombe TE. KRAS Mutation: Should We Test for It, and Does It
Matter? J Clin Oncol 2013;31(8):1112-21.

CONTACTS

Media Enquiries
Neil Burrows         UK/Global                            +44 203 749 5637
Vanessa Rhodes       UK/Global                            +44 203 749 5736
Karen Birmingham     UK/Global                            +44 203 749 5634
Rob Skelding         UK/Global                            +44 203 749 5821
Jacob Lund           Sweden                               +46 8 553 260 20
Michele Meixell      US                                   +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen                                       +44 203 749 5712
Craig Marks          Finance, Fixed Income, M&A           +44 7881 615 764
Nick Stone           Respiratory & Autoimmunity           +44 203 749 5716
Henry Wheeler        Oncology                             +44 203 749 5797
Christer Gruvris     Infection & Neuroscience             +44 203 749 5711
US
Lindsey Trickett     Cardiovascular & Metabolic Diseases  +1 240 543 7970
Mitchell Chan         Oncology                            +1 240 477 3771
Toll free                                                 +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-

Pièces jointes

08097005.pdf